Hematology

Myeloma   

Questions discussed in this category


Is there any data justifying the use of systemic therapy over localized therapy (e.g. radiation or surgery) in this situation prior to a progression e...

For example, for joing replacement surgery? Do you hold the revlimid for certain about of time before and after?

To me, the recent NEJM study is flawed in that the control arm did not have maintenance treatment while the experimental arm used maintenance Dar...

Would you proceed to autologous transplant, or switch to an alternate regimen (eg. daratumumab-based) first? Would the type or degree of organ involv...

Once a tissue biopsy has confirmed light chain amyloid, what additional tests do you perform as part of a standard workup? In whom should treatment b...

Do these events mandate discontinuation of lenalidomide therapy or switching to a different agent? Can appropriate therapy for these skin cancers be r...

Given the PFS benefit seen in the most recent ECOG-ACRIN, and the prior study of Rd showing an OS benefit, is your practice to put any high-risk SMM p...

For example - Would you offer tandem transplantation in a young, fit patient in a CR after first transplant, but with MRD detectable?

Although the MMR vaccine is contraindicated in immunosuppressed patients on anticancer treatment according to CDC/ACIP and IDSA guidelines, data on sa...

Given the recent results presented from the Griffin trial, would you choose a daratumumab-based regimen (eg. D-VRd) over other salvage options (V...

We know the longer we expose patients to lenalidomide, the harder collection will be. Would you collect now or switch to an alternative regimen to ach...

Has the recent data presented at ASH affected your choice of regimen? Would your choice differ between transplant-eligible and transplant-ineligible ...

Would MRD assessments affect your clinical decision making for MM patients outside of a clinical trial?

Specifically, what regimen would you choose in a patient with new renal failure but not requiring dialysis?

Does the choice of initial induction regimen affect your decision for when to employ lenalidomide maintenance? Are there situations where you would c...

Given the rarity of this diagnosis (5-7% of all AL amyloidosis cases), and the prognostic and clinical differences when compared to non IgM-AL am...

Once you decide to begin treatment, any special precautions you would use for protein levels starting that high.

Subq has been shown to have lower risk of neuropathy. Is there any reason to use weekly IV still?

In a patient with multiple poor risk features including TP53 mutation, 1q amplification, stage III, and circulating plasma cells, would you consider a...

For example, how significant does the M protein have to increase for you to begin a conversation about new therapy?

Specifically, to you lean towards elotuzumab or a daratumumab-based regimen?

At what point is the neuropathy a contraindication to further bortezomib therapy?


Papers discussed in this category


JAMA, 2013-04-03

Haematologica, 2016-12-01

Clin Pharmacokinet, 2012-12-01

Blood, 2016-12-22

The New England journal of medicine, 2015-08-13

The Lancet. Oncology, 2010-01

The New England journal of medicine, 2014-09-04

The New England journal of medicine, 2019-05-30

Lancet (London, England), 2017-02-04

The New England journal of medicine, 2018-02-08

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-10-10

The New England journal of medicine, 2017-04-06

Haematologica, 2011 Nov 04

Clin. Cancer Res., 2011 Feb 16

J. Clin. Oncol., 2013 Oct 21

Bone marrow transplantation, 2018-07

Blood, 2016 Mar 21

N. Engl. J. Med.,

Leukemia, 2014-03

The Lancet. Oncology, 2014-03

The New England journal of medicine, 2012-05-10

Leukemia, 2019-01

J Hematol Oncol, 2018 Jan 16

Blood, 2017-07-06

The Lancet. Oncology, 2019-06